Back to companies

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Krka dd Novo Mesto (Krka) is a generic pharmaceutical company that focuses on the development, production, marketing, and sales of human health products, animal health products, and health resort and tourist services. The company's products include prescription pharmaceuticals, non-prescription products, and animal health products. Its product portfolio addresses various therapeutic areas, including cardiovascular, gastrointestinal, central nervous system, pain management, diabetes, and cough and cold treatments. Krka's products are used by a wide range of customers, including healthcare providers and patients, to treat common diseases and health conditions. The company markets its products under the brands Ramladio, Valsamtrio, Sigrada, Coprenessa, Nolpaza, Perineva, Amlessa, Roswera, Doreta, Valsacor, Telmista, Prenessa, Asentra and Ravalsyo and others. It operates in Poland, Croatia, Germany, and China. Krka is headquartered in Novo mesto, Slovenia.

Gain a 360-degree view of Krka dd Novo Mesto and make more informed decisions for your business Gain a 360-degree view of Krka dd Novo Mesto and make more informed decisions for your business Register your interest
Headquarters Slovenia

Address Smarjeska Cesta 6, Novo Mesto, 8501


Telephone 386 7 3312111

No of Employees 13,204

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange KRKG (LJE)

Revenue (2024) $2.3B 6.9% (2024 vs 2023)

EPS XYZ

Net Income (2024) XYZ 13% (2024 vs 2023)

Market Cap* $9.4B

Net Profit Margin (2024) XYZ 5.7% (2024 vs 2023)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Krka dd Novo Mesto premium industry data and analytics

280+

Marketed Drugs

Understand Krka dd Novo Mesto’s commercialized product portfolio to stay one step ahead of the market.

200+

Clinical Trials

Determine Krka dd Novo Mesto go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

12+

Catalyst Calendar

Proactively evaluate Krka dd Novo Mesto’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Krka dd Novo Mesto’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Prescription Co-Diimestra
Cardiovascular Agents Adolax
Blood and Blood Forming Products Nolpaza
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Krka dd Novo Mesto portfolio and identify potential areas for collaboration Understand Krka dd Novo Mesto portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Krka dd Novo Mesto Salus Ljubljana d.d. Bioton SA Nabriva Therapeutics Plc Lek Pharmaceuticals dd
Headquarters Slovenia Slovenia Poland Ireland Slovenia
City Novo Mesto Ljubljana Ożarów Mazowiecki Dublin Ljubljana
No. of Employees 13,204 723 363 39 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Joze Mermal Chairman Executive Board - -
Joze Colaric President; Chief Executive Officer; Director Executive Board - -
Mateja Vrecer Director; Deputy President; Director - Quality Management Executive Board - -
David Bratoz Member Senior Management - -
Davor M. Kalin Director - Key Market Germany Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Krka dd Novo Mesto key executives to enhance your sales strategy Gain insight into Krka dd Novo Mesto key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?